Breaking News Bar

Business News and Information

PhaseBio makes 'extremely difficult' decision to discontinue trial for its experimental Covid-19 therapeutic

The new drug candidate will continue to be developed as a potential treatment for pulmonary arterial hypertension.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear